生物技术公司CytomX Therapeutics Inc(纳斯达克代码:CTMX)迎来重大利好——投资银行摩根大通最新发布研究报告,将其投资评级从"中性"显著上调至"增持"。与此同时,该机构将其目标股价从原先的7美元大幅调升至12美元,增幅超过70%,显示出对该公司未来发展前景的强烈信心。
生物技术公司CytomX Therapeutics Inc(纳斯达克代码:CTMX)迎来重大利好——投资银行摩根大通最新发布研究报告,将其投资评级从"中性"显著上调至"增持"。与此同时,该机构将其目标股价从原先的7美元大幅调升至12美元,增幅超过70%,显示出对该公司未来发展前景的强烈信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.